Belgium's UCB to buy Ra Pharmaceuticals in $2.1 billion cash deal

Belgium's UCB to buy Ra Pharmaceuticals in $2.1 billion cash deal
Reuters: Health
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology.